The role of gastrointestinal hormones in hepatic lipid metabolism

Seminars in Liver Disease

Volumn 33, Issue 4, 2013, Pages 343-357

  Mells, Jamie Eugene ^a   Anania, Frank A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

enteroendocrine cells; glucagon like peptide 1 (GLP 1); lipotoxicity; neuropeptide YY (NPY); nonalcoholic fatty liver disease

Indexed keywords

BILE ACID; BILE SALT; CHOLECYSTOKININ; EXENDIN 4; FATTY ACID; FATTY ACID SYNTHASE; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 2; INCRETIN; INITIATION FACTOR 2ALPHA; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOUNSATURATED FATTY ACID; NEUROPEPTIDE Y; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PLACEBO; SEROTONIN; SOMATOSTATIN; TRIACYLGLYCEROL;

APOPTOSIS; APPETITE; ARTICLE; BARIATRIC SURGERY; BODY MASS; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ENERGY EXPENDITURE; ENTEROENDOCRINE CELL; ESSENTIAL HYPERTENSION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FOOD INTAKE; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE MOTILITY; LIPID ABSORPTION; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOGENESIS; LIPOPHAGOCYTOSIS; LIPOTOXICITY; LIVER CELL; LIVER METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; SATIETY; SMALL INTESTINE;

ANIMALS; BARIATRIC SURGERY; ENTEROENDOCRINE CELLS; FATTY LIVER; GASTROINTESTINAL HORMONES; HUMANS; LIPID METABOLISM; LIVER; OBESITY; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION;

EID: 84887579055     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1358527     Document Type: Article

References (158)

1. O'Grady M. J., Capretta J. C. Assessing the Economics of Obesity and Obesity Interventions. Campaign to End Obesity. Princeton, NJ Robert Wood Johnson Foundation: 2012; 1 40
2. Flegal K. M. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav: 2005; 86 5 599 602
3. Flegal K. M. Excess deaths associated with obesity: cause and effect. Int J Obes (Lond): 2006; 30 8 1171 1172
4. Flegal K. M., Graubard B. I., Williamson D. F., Gail M. H. Excess deaths associated with underweight, overweight, and obesity. JAMA: 2005; 293 15 1861 1867
5. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis: 2010; 28 1 155 161
6. Chen K., Lindsey J. B., Khera A., et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. Diab Vasc Dis Res: 2008; 5 2 96 101
7. Monda K. L., North K. E., Hunt S. C., Rao D. C., Province M. A., Kraja A. T. The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets: 2010; 10 2 86 108
8. Bastard J. P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw: 2006; 17 1 4 12
9. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab: 2008; 34 6 Pt 2 649 657
10. Hiltunen J. K., Autio K. J., Schonauer M. S., Kursu V. A., Dieckmann C. L., Kastaniotis A. J. Mitochondrial fatty acid synthesis and respiration. Biochim Biophys Acta: 2010; 1797 6-7 1195 1202
11. Trauner M., Arrese M., Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta: 2010; 1801 3 299 310
12. Malhi H., Bronk S. F., Werneburg N. W., Gores G. J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem: 2006; 281 17 12093 12101
13. Ricchi M., Odoardi M. R., Carulli L., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol: 2009; 24 5 830 840
14. Chavez-Tapia N. C., Rosso N., Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol: 2012; 12 20
15. Henkel A., Green R. M. The unfolded protein response in fatty liver disease. Sem Liver Dis: 2013; 33 321 329
16. Wang D., Wei Y., Pagliassotti M. J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology: 2006; 147 2 943 951
17. Wei Y., Wang D., Topczewski F., Pagliassotti M. J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab: 2006; 291 2 E275 E281
18. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol: 2005; 6 1 79 87
19. Czaja M. J., Ding W. X., Donohue T. M., et al. Functions of autophagy in normal and diseased liver. Autophagy: 2013; 9 8 1131 1158
20. Drucker D. J., Lovshin J., Baggio L., et al. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann N Y Acad Sci: 2000; 921 226 232
21. Baggio L. L., Drucker D. J. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat Endocrinol: 2002; 1 2 117 125
22. Brubaker P. L., Drucker D. J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology: 2004; 145 6 2653 2659
23. Drucker D. J. The role of gut hormones in glucose homeostasis. J Clin Invest: 2007; 117 1 24 32
24. Baggio L. L., Holland D., Wither J., Drucker D. J. Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice. Diabetes: 2006; 55 6 1562 1570
25. Moran G. W., Leslie F. C., Levison S. E., Worthington J., McLaughlin J. T. Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol: 2008; 1 1 51 60
26. Sternini C., Anselmi L., Rozengurt E. Enteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes: 2008; 15 1 73 78
27. Habib A. M., Richards P., Cairns L. S., et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology: 2012; 153 7 3054 3065
28. Li H. J., Ray S. K., Singh N. K., Johnston B., Leiter A. B. Basic helix-loop-helix transcription factors and enteroendocrine cell differentiation. Diabetes Obes Metab: 2011; 13 01 5 12
29. Gunawardene A. R., Corfe B. M., Staton C. A. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol: 2011; 92 4 219 231
30. Ahlman H., Nilsson. The gut as the largest endocrine organ in the body. Ann Oncol: 2001; 12 02 S63 S68
31. Sykaras A. G., Demenis C., Case R. M., McLaughlin J. T., Smith C. P. Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS ONE: 2012; 7 8 e42373
32. Moran-Ramos S., Tovar A. R., Torres N. Diet: friend or foe of enteroendocrine cells-how it interacts with enteroendocrine cells. Adv Nutr: 2012; 3 1 8 20
33. Gutierrez-Aguilar R., Woods S. C. Nutrition and L and K-enteroendocrine cells. Curr Opin Endocrinol Diabetes Obes: 2011; 18 1 35 41
34. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature: 2005; 435 7044 964 968
35. May C. L., Kaestner K. H. Gut endocrine cell development. Mol Cell Endocrinol: 2010; 323 1 70 75
36. Barker N., van Es J. H., Kuipers J., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature: 2007; 449 7165 1003 1007
37. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA: 2004; 292 14 1724 1737
38. Buchwald H., Estok R., Fahrbach K., Banel D., Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery: 2007; 142 4 621 632, discussion 632-635
39. Buchwald H., Estok R., Fahrbach K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med: 2009; 122 3 248 256, e5
40. Maggard-Gibbons M., Maglione M., Livhits M., et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA: 2013; 309 21 2250 2261
41. O'Brien P. E. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol: 2010; 25 8 1358 1365
42. Field B. C., Chaudhri O. B., Bloom S. R. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol: 2010; 6 8 444 453
43. Hng K. N., Ang Y. S. Overview of bariatric surgery for the physician. Clin Med: 2012; 12 5 435 440
44. Falkén Y., Hellström P. M., Holst J. J., Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab: 2011; 96 7 2227 2235
45. Barker K. B., Palekar N. A., Bowers S. P., Goldberg J. E., Pulcini J. P., Harrison S. A. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol: 2006; 101 2 368 373
46. Tiikkainen M., Bergholm R., Vehkavaara S., et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes: 2003; 52 3 701 707
47. Göke R., Fehmann H. C., Linn T., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem: 1993; 268 26 19650 19655
48. Pohl M., Wank S. A. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem: 1998; 273 16 9778 9784
49. Mentlein R., Gallwitz B., Schmidt W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem: 1993; 214 3 829 835
50. Deacon C. F., Johnsen A. H., Holst J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab: 1995; 80 3 952 957
51. Drucker D. J. Glucagon-like peptides. Diabetes: 1998; 47 2 159 169
52. Maruyama T., Miyamoto Y., Nakamura T., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun: 2002; 298 5 714 719
53. Graziano M. P., Hey P. J., Borkowski D., Chicchi G. G., Strader C. D. Cloning and functional expression of a human glucagon-like peptide-1 receptor. Biochem Biophys Res Commun: 1993; 196 1 141 146
54. Dillon J. S., Tanizawa Y., Wheeler M. B., et al. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology: 1993; 133 4 1907 1910
55. Arnés L., González N., Tornero-Esteban P., et al. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med: 2008; 22 1 127 132
56. Baggio L. L., Drucker D. J. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab: 2004; 18 4 531 554
57. Brubaker P. L., Drucker D. J. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels: 2002; 8 3-4 179 188
58. Baggio L., Kieffer T. J., Drucker D. J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology: 2000; 141 10 3703 3709
59. Drucker D. J. Minireview: the glucagon-like peptides. Endocrinology: 2001; 142 2 521 527
60. Flint A., Raben A., Astrup A., Holst J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest: 1998; 101 3 515 520
61. Gupta N. A., Mells J., Dunham R. M., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology: 2010; 51 5 1584 1592
62. Thorens B., Porret A., Bühler L., Deng S. P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes: 1993; 42 11 1678 1682
63. Mells J. E., Fu P. P., Sharma S., et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol: 2012; 302 2 G225 G235
64. Svegliati-Baroni G., Saccomanno S., Rychlicki C., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int: 2011; 31 9 1285 1297
65. Pedersen J., Holst J. J. Glucagon like-peptide 1 receptor and the liver. Liver Int: 2011; 31 9 1243 1245
66. Vendrell J., El Bekay R., Peral B., et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology: 2011; 152 11 4072 4079
67. Ding X., Saxena N. K., Lin S., Gupta N. A., Anania F. A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology: 2006; 43 1 173 181
68. Panjwani N., Mulvihill E. E., Longuet C., et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology: 2013; 154 1 127 139
69. Sharma S., Mells J. E., Fu P. P., Saxena N. K., Anania F. A. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE: 2011; 6 9 e25269
70. Yamanaka-Okumura H., Urano E., Kawaura A., et al. Treatment of rapid weight loss in a donor with hepatic steatosis in living donor liver transplantation: a case report. Hepatogastroenterology: 2012; 59 115 869 871
71. Nativ N. I., Maguire T. J., Yarmush G., et al. Liver defatting: an alternative approach to enable steatotic liver transplantation. Am J Transplant: 2012; 12 12 3176 3183
72. Trevaskis J. L., Griffin P. S., Wittmer C., et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol: 2012; 302 8 G762 G772
73. Cho Y. M., Kieffer T. J. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm: 2010; 84 111 150
74. McIntosh C. H., Widenmaier S., Kim S. J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm: 2009; 80 409 471
75. Rao R. S., Kini S. GIP and bariatric surgery. Obes Surg: 2011; 21 2 244 252
76. Baggio L. L., Drucker D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology: 2007; 132 6 2131 2157
77. Musso G., Gambino R., Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med: 2010; 61 375 392
78. Reimann F. Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int Dairy J: 2010; 20 4 236 242
79. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med: 2002; 8 7 738 742
80. Paschetta E., Hvalryg M., Musso G. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders. Obes Rev: 2011; 12 10 813 828
81. García-Jiménez C. Wnt and incretin connections. Vitam Horm: 2010; 84 355 387
82. Miyawaki K., Yamada Y., Yano H., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A: 1999; 96 26 14843 14847
83. Nie Y., Ma R. C., Chan J. C., Xu H., Xu G. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J: 2012; 26 6 2383 2393
84. Timper K., Grisouard J., Sauter N. S., et al. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab: 2013; 304 1 E1 E13
85. Asmar M. New physiological effects of the incretin hormones GLP-1 and GIP. Dan Med Bull: 2011; 58 2 B4248
86. Asmar M., Simonsen L., Madsbad S., Stallknecht B., Holst J. J., Bülow J. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes: 2010; 59 9 2160 2163
87. Asmar M., Simonsen L., Arngrim N., Holst J. J., Dela F., Bülow J. Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes (Lond): 2013
88. Musso G., Gambino R., Pacini G., De Michieli F., Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr: 2009; 89 2 558 567
89. Estall J. L., Drucker D. J. Glucagon-like peptide-2. Annu Rev Nutr: 2006; 26 391 411
90. Drucker D. J. Glucagon-like peptide 2. J Clin Endocrinol Metab: 2001; 86 4 1759 1764
91. Wallis K., Walters J. R., Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther: 2007; 25 4 365 372
92. Yusta B., Huang L., Munroe D., et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology: 2000; 119 3 744 755
93. Meier J. J., Nauck M. A., Pott A., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology: 2006; 130 1 44 54
94. Mellitzer G., Gradwohl G. Enteroendocrine cells and lipid absorption. Curr Opin Lipidol: 2011; 22 3 171 175
95. McCuskey R. S. Anatomy of efferent hepatic nerves. Anat Rec A Discov Mol Cell Evol Biol: 2004; 280 1 821 826
96. Ding W. G., Kitasato H., Kimura H. Development of neuropeptide Y innervation in the liver. Microsc Res Tech: 1997; 39 4 365 371
97. Larhammar D., Salaneck E. Molecular evolution of NPY receptor subtypes. Neuropeptides: 2004; 38 4 141 151
98. Hsieh J., Longuet C., Maida A., et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology: 2009; 137 3 997 1005, e1-e4
99. Hein G. J., Baker C., Hsieh J., Farr S., Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes: 2013; 62 2 373 381
100. Degrace P., Moindrot B., Mohamed I., et al. Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid. J Lipid Res: 2006; 47 12 2647 2655
101. Buqué X., Martínez M. J., Cano A., et al. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res: 2010; 51 3 500 513
102. Miquilena-Colina M. E., Lima-Cabello E., Sánchez-Campos S., et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut: 2011; 60 10 1394 1402
103. Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol: 2012; 215 3 335 346
104. Drucker D. J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab: 2005; 1 1 22 31
105. Santoprete A., Capitò E., Carrington P. E., et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci: 2011; 17 4 270 280
106. ThanThan S., Asada Y., Saito T., et al. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle. Domest Anim Endocrinol: 2013; 44 2 70 80
107. Baggio L. L., Huang Q., Brown T. J., Drucker D. J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology: 2004; 127 2 546 558
108. Jorgensen R., Kubale V., Vrecl M., Schwartz T. W., Elling C. E. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther: 2007; 322 1 148 154
109. Bataille D., Gespach C., Tatemoto K., et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides: 1981; 2 02 41 44
110. Gespach C., Bataille D., Vauclin N., Rosselin G., Moroder L., Wünsch E. Secretin binding sites coupled with adenylate cyclase in rat fundic membranes. Peptides: 1981; 2 02 247 251
111. Koole C., Wootten D., Simms J., et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol: 2010; 78 3 456 465
112. Gehlert D. R. Introduction to the reviews on neuropeptide Y. Neuropeptides: 2004; 38 4 135 140
113. Chandarana K., Batterham R. Peptide YY. Curr Opin Endocrinol Diabetes Obes: 2008; 15 1 65 72
114. Balasubramaniam A. A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides: 1997; 18 3 445 457
115. Mullins D. E., Zhang X., Hawes B. E. Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul Pept: 2002; 105 1 65 73
116. Lin S., Boey D., Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides: 2004; 38 4 189 200
117. Holzer P., Reichmann F., Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides: 2012; 46 6 261 274
118. Chee M. J., Colmers W. F. Y eat? Nutrition: 2008; 24 9 869 877
119. Lin S., Boey D., Couzens M., Lee N., Sainsbury A., Herzog H. Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides: 2005; 39 1 21 28
120. Lin S., Boey D., Lee N., Schwarzer C., Sainsbury A., Herzog H. Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuropeptides: 2006; 40 2 115 123
121. Lindner D., Stichel J., Beck-Sickinger A. G. Molecular recognition of the NPY hormone family by their receptors. Nutrition: 2008; 24 9 907 917
122. Lindner D., van Dieck J., Merten N., et al. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochemistry: 2008; 47 22 5905 5914
123. Herzog H., Hort Y. J., Ball H. J., Hayes G., Shine J., Selbie L. A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A: 1992; 89 13 5794 5798
124. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides: 2004; 38 4 213 224
125. van den Hoek A. M., van Heijningen C., Schröder-van der Elst J. P., et al. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes: 2008; 57 9 2304 2310
126. van den Hoek A. M., Voshol P. J., Karnekamp B. N., et al. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes: 2004; 53 10 2529 2534
127. Sigala B., McKee C., Soeda J., et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS ONE: 2013; 8 9 e72928
128. de Piano A., Tock L., Carnier J., et al. The role of nutritional profile in the orexigenic neuropeptide secretion in nonalcoholic fatty liver disease obese adolescents. Eur J Gastroenterol Hepatol: 2010; 22 5 557 563
129. Garruti G., Cotecchia S., Giampetruzzi F., Giorgino F., Giorgino R. Neuroendocrine deregulation of food intake, adipose tissue and the gastrointestinal system in obesity and metabolic syndrome. J Gastrointestin Liver Dis: 2008; 17 2 193 198
130. Garruti G., Giusti V., Nussberger J., et al. Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes. Obesity (Silver Spring): 2007; 15 9 2181 2189
131. El-Salhy M., Mazzawi T., Gundersen D., Hatlebakk J. G., Hausken T. The role of peptide YY in gastrointestinal diseases and disorders (review). (review) Int J Mol Med: 2013; 31 2 275 282
132. Bradley W. D., Zwingelstein C., Rondinone C. M. The emerging role of the intestine in metabolic diseases. Arch Physiol Biochem: 2011; 117 3 165 176
133. Rabl C., Campos G. M. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis: 2012; 32 1 80 91
134. El-Salhy M., Falkmer S., Kramer K. J., Speirs R. D. Immunocytochemical evidence for the occurrence of insulin in the frontal ganglion of a Lepidopteran insect, the tobacco hornworm moth, Manduca sexta L. Gen Comp Endocrinol: 1984; 54 1 85 88
135. El-Salhy M. Immunocytochemical investigation of the gastro-entero- pancreatic (GEP) neurohormonal peptides in the pancreas and gastrointestinal tract of the dogfish Squalus acanthias. Histochemistry: 1984; 80 2 193 205
136. Dong C. X., Brubaker P. L. Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol: 2012; 9 12 705 715
137. Batterham R. L., Cohen M. A., Ellis S. M., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med: 2003; 349 10 941 948
138. Koda S., Date Y., Murakami N., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology: 2005; 146 5 2369 2375
139. Batterham R. L., Cowley M. A., Small C. J., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature: 2002; 418 6898 650 654
140. Maas M. I., Hopman W. P., Katan M. B., Jansen J. B. Release of peptide YY and inhibition of gastric acid secretion by long-chain and medium-chain triglycerides but not by sucrose polyester in men. Eur J Clin Invest: 1998; 28 2 123 130
141. Halldén G., Aponte G. W. Evidence for a role of the gut hormone PYY in the regulation of intestinal fatty acid-binding protein transcripts in differentiated subpopulations of intestinal epithelial cell hybrids. J Biol Chem: 1997; 272 19 12591 12600
142. Onaga T., Zabielski R., Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides: 2002; 23 2 279 290
143. Pedersen S. L., Sasikumar P. G., Chelur S., et al. Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice. J Pept Sci: 2010; 16 11 664 673
144. Shi Y. C., Hämmerle C. M., Lee I. C., et al. Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity. Neuropeptides: 2012; 46 4 173 182
145. Asakawa A., Inui A., Yuzuriha H., et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology: 2003; 124 5 1325 1336
146. Stanley S., Wynne K., Bloom S. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol: 2004; 286 5 G693 G697
147. Zac-Varghese S., Tan T., Bloom S. R. Hormonal interactions between gut and brain. Discov Med: 2010; 10 55 543 552
148. Cox H. M. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton Neurosci: 2007; 133 1 76 85
149. Simpson K., Parker J., Plumer J., Bloom S. CCK, PYY and PP: the control of energy balance. Handbook Exp Pharmacol: 2012; 209 209 230
150. Adrian T. E., Bloom S. R., Bryant M. G., Polak J. M., Heitz P. H., Barnes A. J. Distribution and release of human pancreatic polypeptide. Gut: 1976; 17 12 940 944
151. Asakawa A., Inui A., Ueno N., Fujimiya M., Fujino M. A., Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides: 1999; 20 12 1445 1448
152. Kojima S., Ueno N., Asakawa A., et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides: 2007; 28 2 459 463
153. Gerald C., Walker M. W., Criscione L., et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature: 1996; 382 6587 168 171
154. Lin S., Shi Y. C., Yulyaningsih E., et al. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS ONE: 2009; 4 12 e8488
155. Lassmann V., Vague P., Vialettes B., Simon M. C. Low plasma levels of pancreatic polypeptide in obesity. Diabetes: 1980; 29 6 428 430
156. Uhe A. M., Szmukler G. I., Collier G. R., Hansky J., O'Dea K., Young G. P. Potential regulators of feeding behavior in anorexia nervosa. Am J Clin Nutr: 1992; 55 1 28 32
157. Suzuki K., Jayasena C. N., Bloom S. R. Obesity and appetite control. Exp Diabetes Res: 2012; 2012 824305
158. Phillips J. K., McLean A. J., Hill C. E. Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery. Br J Pharmacol: 1998; 124 7 1403 1412